Phosmet

DB11448

small molecule vet_approved

Deskripsi

Phosmet is a phthalimide-derived organophosphate. It is a non-specific insecticide. It is mainly used on apple trees to control codling moths. It is also used on other fruit crops, ornamentals, and vines to control aphids, suckers, mites, and fruit flies.

Struktur Molekul 2D

Berat 317.31
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

368 Data
Leuprolide The risk or severity of QTc prolongation can be increased when Phosmet is combined with Leuprolide.
Goserelin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Goserelin.
Erythromycin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Erythromycin.
Azithromycin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Azithromycin.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Moxifloxacin.
Ranolazine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Ranolazine.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Phosmet is combined with Sulfisoxazole.
Amitriptyline The risk or severity of QTc prolongation can be increased when Phosmet is combined with Amitriptyline.
Methadone The risk or severity of QTc prolongation can be increased when Phosmet is combined with Methadone.
Diltiazem The risk or severity of QTc prolongation can be increased when Phosmet is combined with Diltiazem.
Clozapine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Clozapine.
Sulpiride The risk or severity of QTc prolongation can be increased when Phosmet is combined with Sulpiride.
Nimodipine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Nimodipine.
Promazine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Promazine.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Prochlorperazine.
Droperidol The risk or severity of QTc prolongation can be increased when Phosmet is combined with Droperidol.
Imipramine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Imipramine.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Chlorpromazine.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Phosmet.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Ciprofloxacin.
Fluorouracil The risk or severity of QTc prolongation can be increased when Phosmet is combined with Fluorouracil.
Perflutren The risk or severity of QTc prolongation can be increased when Phosmet is combined with Perflutren.
Cinnarizine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Cinnarizine.
Atropine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Atropine.
Chloroquine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Chloroquine.
Efavirenz The risk or severity of QTc prolongation can be increased when Phosmet is combined with Efavirenz.
Adenosine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Adenosine.
Pentamidine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Pentamidine.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Phosmet is combined with Gadobenic acid.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Carbinoxamine.
Dolasetron The risk or severity of QTc prolongation can be increased when Phosmet is combined with Dolasetron.
Roxithromycin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Roxithromycin.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Phosmet is combined with Nalidixic acid.
Cinoxacin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Cinoxacin.
Loperamide The risk or severity of QTc prolongation can be increased when Phosmet is combined with Loperamide.
Granisetron The risk or severity of QTc prolongation can be increased when Phosmet is combined with Granisetron.
Ondansetron The risk or severity of QTc prolongation can be increased when Phosmet is combined with Ondansetron.
Levosimendan The risk or severity of QTc prolongation can be increased when Phosmet is combined with Levosimendan.
Mesoridazine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Mesoridazine.
Desloratadine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Desloratadine.
Telithromycin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Telithromycin.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Lomefloxacin.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Phosmet is combined with Dimenhydrinate.
Primaquine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Primaquine.
Papaverine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Papaverine.
Chlorpheniramine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Chlorpheniramine.
Nifedipine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Nifedipine.
Levofloxacin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Levofloxacin.
Gemifloxacin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Gemifloxacin.
Ofloxacin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Ofloxacin.
Propafenone The risk or severity of QTc prolongation can be increased when Phosmet is combined with Propafenone.
Flecainide The risk or severity of QTc prolongation can be increased when Phosmet is combined with Flecainide.
Clarithromycin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Clarithromycin.
Levacetylmethadol The risk or severity of QTc prolongation can be increased when Phosmet is combined with Levacetylmethadol.
Saquinavir The risk or severity of QTc prolongation can be increased when Phosmet is combined with Saquinavir.
Clomipramine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Clomipramine.
Mibefradil The risk or severity of QTc prolongation can be increased when Phosmet is combined with Mibefradil.
Probucol The risk or severity of QTc prolongation can be increased when Phosmet is combined with Probucol.
Aceprometazine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Aceprometazine.
Terlipressin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Terlipressin.
Prenylamine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Prenylamine.
Fluspirilene The risk or severity of QTc prolongation can be increased when Phosmet is combined with Fluspirilene.
Lofexidine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Lofexidine.
Azimilide The risk or severity of QTc prolongation can be increased when Phosmet is combined with Azimilide.
Pracinostat The risk or severity of QTc prolongation can be increased when Phosmet is combined with Pracinostat.
Technetium Tc-99m ciprofloxacin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Technetium Tc-99m ciprofloxacin.
Garenoxacin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Garenoxacin.
Tedisamil The risk or severity of QTc prolongation can be increased when Phosmet is combined with Tedisamil.
Tucidinostat The risk or severity of QTc prolongation can be increased when Phosmet is combined with Tucidinostat.
Telavancin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Telavancin.
Pazopanib The risk or severity of QTc prolongation can be increased when Phosmet is combined with Pazopanib.
Nemonoxacin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Nemonoxacin.
Panobinostat The risk or severity of QTc prolongation can be increased when Phosmet is combined with Panobinostat.
Nilvadipine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Nilvadipine.
Antazoline The risk or severity of QTc prolongation can be increased when Phosmet is combined with Antazoline.
Crizotinib The risk or severity of QTc prolongation can be increased when Phosmet is combined with Crizotinib.
Bedaquiline The risk or severity of QTc prolongation can be increased when Phosmet is combined with Bedaquiline.
Fendiline The risk or severity of QTc prolongation can be increased when Phosmet is combined with Fendiline.
Eperisone The risk or severity of QTc prolongation can be increased when Phosmet is combined with Eperisone.
Butriptyline The risk or severity of QTc prolongation can be increased when Phosmet is combined with Butriptyline.
Ceritinib The risk or severity of QTc prolongation can be increased when Phosmet is combined with Ceritinib.
Lenvatinib The risk or severity of QTc prolongation can be increased when Phosmet is combined with Lenvatinib.
Melperone The risk or severity of QTc prolongation can be increased when Phosmet is combined with Melperone.
Benidipine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Benidipine.
Dexchlorpheniramine maleate The risk or severity of QTc prolongation can be increased when Phosmet is combined with Dexchlorpheniramine maleate.
Amifampridine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Amifampridine.
Mocetinostat The risk or severity of QTc prolongation can be increased when Phosmet is combined with Mocetinostat.
Entinostat The risk or severity of QTc prolongation can be increased when Phosmet is combined with Entinostat.
Gilteritinib The risk or severity of QTc prolongation can be increased when Phosmet is combined with Gilteritinib.
CUDC-101 The risk or severity of QTc prolongation can be increased when Phosmet is combined with CUDC-101.
Simendan The risk or severity of QTc prolongation can be increased when Phosmet is combined with Simendan.
Ricolinostat The risk or severity of QTc prolongation can be increased when Phosmet is combined with Ricolinostat.
Mizolastine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Mizolastine.
Abexinostat The risk or severity of QTc prolongation can be increased when Phosmet is combined with Abexinostat.
Oxatomide The risk or severity of QTc prolongation can be increased when Phosmet is combined with Oxatomide.
Sitafloxacin The risk or severity of QTc prolongation can be increased when Phosmet is combined with Sitafloxacin.
Sultopride The risk or severity of QTc prolongation can be increased when Phosmet is combined with Sultopride.
Otilonium The risk or severity of QTc prolongation can be increased when Phosmet is combined with Otilonium.
Nizofenone The risk or severity of QTc prolongation can be increased when Phosmet is combined with Nizofenone.
Bunaftine The risk or severity of QTc prolongation can be increased when Phosmet is combined with Bunaftine.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 21588425
    Cheon S, Yang H, Park KM, Kim TH, Kim J: Phosmet: O,O-dimethyl S-phthalimidomethyl phospho-rodithio-ate. Acta Crystallogr Sect E Struct Rep Online. 2010 Jul 31;66(Pt 8):o2137. doi: 10.1107/S1600536810029338.
  • PMID: 13129307
    Sinderhauf K, Schwack W: Photolysis experiments on phosmet, an organophosphorus insecticide. J Agric Food Chem. 2003 Sep 24;51(20):5990-5.
  • PMID: 7458565
    Bleyl DW: Embryotoxicity and teratogenicity of phosmet in mice. Arch Exp Veterinarmed. 1980;34(5):791-5.
  • PMID: 146931
    Warren BC, Yeoman GH: Phosmet as a warble control agent. Vet Rec. 1977 Dec 17;101(25):504-5.
  • PMID: 21870875
    Liu C, Gan J, Zhang Y, Liang M, Shu X, Shu J, Yang B: Heterogeneous reaction of suspended phosmet particles with NO3 radicals. J Phys Chem A. 2011 Oct 6;115(39):10744-8. doi: 10.1021/jp205175p. Epub 2011 Sep 14.
  • PMID: 3095071
    Vargova M, Batora I, Jakubovsky J, Kobzova D, Gajdova M, Batorova A, Lipkova V: On the mechanism of acute toxicity of phosmet. Czech Med. 1986;9(3):130-42.
  • PMID: 3203213
    Gajdova M, Vargova M, Jakubovsky J, Grunt J, Valky J, Galbavy S: Estrogenic effect of phosmet on the uterus of neonatal rats. Bratisl Lek Listy. 1988 Nov;89(11):843-7.
  • PMID: 7164333
    Hewett GR, Heard TW: Phosmet for the systemic control of pig mange. Vet Rec. 1982 Dec 11;111(24):558.
Menampilkan 8 dari 9 artikel.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul